Gabay et al. reported that a recombinant human recombinant IL-18BP, which is known as tadekinig alfa, appears to have a favorable safety profile and is associated with early signs of efficacy in patients with AOSD [37]. This evidence concerns the gene IL18BP and adult-onset Still disease.